[Review] Biological therapies for rheumatoid arthritis: An overview for the clinician
| dc.contributor.author | Findeisen, Kate E | |
| dc.contributor.author | Sewell, Julia | |
| dc.contributor.author | Ostor, Andrew | |
| dc.date.accessioned | 2024-02-21T01:53:50Z | |
| dc.date.available | 2024-02-21T01:53:50Z | |
| dc.date.issued | 2021 | |
| dc.date.updated | 2022-10-09T07:17:49Z | |
| dc.description.abstract | Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines. | en_AU |
| dc.format.mimetype | application/pdf | en_AU |
| dc.identifier.issn | 1177-5475 | en_AU |
| dc.identifier.uri | http://hdl.handle.net/1885/313795 | |
| dc.language.iso | en_AU | en_AU |
| dc.provenance | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php) | en_AU |
| dc.publisher | Dove Medical Press Ltd | en_AU |
| dc.rights | © 2021 The authors | en_AU |
| dc.rights.license | Creative Commons Attribution licence | en_AU |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/ | en_AU |
| dc.source | Biologics: Targets and Therapy | en_AU |
| dc.subject | rheumatoid arthritis | en_AU |
| dc.subject | biological therapies | en_AU |
| dc.subject | bDMARDs | en_AU |
| dc.title | [Review] Biological therapies for rheumatoid arthritis: An overview for the clinician | en_AU |
| dc.type | Journal article | en_AU |
| dcterms.accessRights | Open Access | en_AU |
| local.bibliographicCitation.lastpage | 352 | en_AU |
| local.bibliographicCitation.startpage | 343 | en_AU |
| local.contributor.affiliation | Findeisen, Kate E, The Alfred Hospital, Melbourne VIC Australia | en_AU |
| local.contributor.affiliation | Sewell, Julia, The Alfred Hospital, Melbourne VIC Australia | en_AU |
| local.contributor.affiliation | Ostor, Andrew, College of Health and Medicine, ANU | en_AU |
| local.contributor.authoruid | Ostor, Andrew, u1121502 | en_AU |
| local.description.notes | Imported from ARIES | en_AU |
| local.identifier.absfor | 320223 - Rheumatology and arthritis | en_AU |
| local.identifier.absfor | 320402 - Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | en_AU |
| local.identifier.ariespublication | a383154xPUB32824 | en_AU |
| local.identifier.citationvolume | 15 | en_AU |
| local.identifier.doi | 10.2147/BTT.S252575 | en_AU |
| local.identifier.scopusID | 2-s2.0-85113236544 | |
| local.publisher.url | https://www.dovepress.com/ | en_AU |
| local.type.status | Published Version | en_AU |
Downloads
Original bundle
1 - 1 of 1
Loading...
- Name:
- BTT-252575-biological-therapies-for-rheumatoid-arthritis--an-overview-f.pdf
- Size:
- 482.25 KB
- Format:
- Adobe Portable Document Format
- Description: